UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.460

Sortiert nach

Fertility preservation

Breast (Edinburgh), 2021-04, Vol.56, p.S12

Pagani, O.

2021

Volltextzugriff (PDF)

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Annals of oncology, 2020-06, Vol.31 (6), p.674-696

2020

Volltextzugriff (PDF)

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Annals of oncology, 2022-11, Vol.33 (11), p.1097-1118

2022

Volltextzugriff (PDF)

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D

Breast (Edinburgh), 2022-10, Vol.65, p.32-40

2022

Volltextzugriff (PDF)

IN10 What's new in endocrine therapy in young women

Breast (Edinburgh), 2014-11, Vol.23, p.S5-S5

Pagani, O

2014

Volltextzugriff (PDF)

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Annals of oncology, 2022-06, Vol.33 (6), p.658-658

2022

Volltextzugriff (PDF)

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

Annals of oncology, 2017-09, Vol.28 (9), p.2225-2232

2017

Volltextzugriff (PDF)

Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers

Breast (Edinburgh), 2019-10, Vol.47, p.85-92

2019

Volltextzugriff (PDF)

P003 ROSE trial: A prospective non-interventional study to assess the quality of life (QoL) of premenopausal patients with early breast cancer receiving triptorelin as ovarian function suppression

Breast (Edinburgh), 2023-04, Vol.68, p.S15-S16

2023

Volltextzugriff (PDF)

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)

Annals of oncology, 2006-06, Vol.17 (6), p.935-944

2006

Volltextzugriff (PDF)

IN25 Pregnancy registry and trial project

Breast (Edinburgh), 2012-11, Vol.21, p.S9-S9

Pagani, O

2012

Volltextzugriff (PDF)

IN11 Endocrine therapy for early breast cancer

Breast (Edinburgh), 2012-11, Vol.21, p.S4-S4

Pagani, O

2012

Volltextzugriff (PDF)

1st International consensus guidelines for advanced breast cancer (ABC 1)

Breast (Edinburgh), 2012-06, Vol.21 (3), p.242-252

2012

Volltextzugriff (PDF)

SA 8.3 - Fertility preservation

Breast (Edinburgh), 2021-04, Vol.56, p.S12-S12

Pagani, O.

2021

Volltextzugriff (PDF)

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

Annals of oncology, 2017-02, Vol.28 (2), p.305-312

2017

Volltextzugriff (PDF)

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of oncology, 2018-03, Vol.29 (3), p.661-668

2018

Volltextzugriff (PDF)

Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey

Annals of oncology, 2018-10, Vol.29, p.viii606-viii606

2018

Volltextzugriff (PDF)

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials

Breast (Edinburgh), 2019-08, Vol.46, p.19-24

2019

Volltextzugriff (PDF)

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials

Annals of oncology, 2007-04, Vol.18 (4), p.701-708

2007

Volltextzugriff (PDF)

Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: a literature based meta-analysis of randomized trials

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi34

2017

Volltextzugriff (PDF)

Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)

Annals of oncology, 2018-10, Vol.29, p.viii609-viii610

2018

Volltextzugriff (PDF)

Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)

Annals of oncology, 2012-06, Vol.23 (6), p.1474-1481

2012

Volltextzugriff (PDF)

Corrections to “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017”

Annals of oncology, 2019-07, Vol.30 (7), p.1181-1181

2019

Volltextzugriff (PDF)

Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel

Cancer treatment reviews, 2011-04, Vol.37 (2), p.97-104

2011

Volltextzugriff (PDF)

A survey on physicians’ knowledge, practice and attitudes on fertility and pregnancy issues in young breast cancer patients

Breast (Edinburgh), 2017-03, Vol.32, p.S85-S86

2017

Volltextzugriff (PDF)

1 – 25 von 1.460

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(872)
Mit Volltextzugriff
(1.049)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Fertility preservation

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D

IN10 What's new in endocrine therapy in young women

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers

P003 ROSE trial: A prospective non-interventional study to assess the quality of life (QoL) of premenopausal patients with early breast cancer receiving triptorelin as ovarian function suppression

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)

IN25 Pregnancy registry and trial project

IN11 Endocrine therapy for early breast cancer

1st International consensus guidelines for advanced breast cancer (ABC 1)

SA 8.3 - Fertility preservation

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials

Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: a literature based meta-analysis of randomized trials

Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)

Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)

Corrections to “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017”

Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel

A survey on physicians’ knowledge, practice and attitudes on fertility and pregnancy issues in young breast cancer patients

Suchergebnisse filtern